Webb10 apr. 2024 · Introduction: In recent years, purinergic signaling via the P2X7 receptor (P2X7R) on microglia has repeatedly been implicated in depression genesis. However, it remains unclear which role the human P2X7R (hP2X7R) plays in regulating both microglia morphology and cytokine secretion upon different environmental and immune stimuli, … WebbOur aim was to investigate whether there is an interaction between IL-6 and nucleotide signaling, in particular, that mediated by the ATP-sensing P2X7 receptor (P2X7R). Using human cell lines of PSCs and cancer cells, as well as primary PSCs from mice, we show that ATP is released from both PSCs and cancer cells in response to mechanical and …
Frontiers The P2X7 Receptor Is Shed Into Circulation: …
Webb1 apr. 2024 · The P2X7 receptor (P2X7R) is a key pro-inflammatory plasma membrane receptor responsible for NLRP3 inflammasome activation and IL-1β release. Various … Webb16 dec. 2024 · A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress … ip location trace
Frontiers The P2X7 Receptor: Central Hub of Brain Diseases
Webb17 maj 2024 · The purinergic P2X7 receptor (P2X7R) is an ATP-sensitive ionic channel that is highly expressed in microglia and is fundamental to microglial activation, ... Therefore, knock-in mouse models have been created by introducing the R151X mutation into exon 5 of the mouse PPT1 gene [12,13]. WebbThe P2X7 receptor (P2X7R) is a key pro-inflammatory plasma membrane receptor responsible for NLRP3 inflammasome activation and IL-1β release. Various inflammatory plasma membrane receptors (e.g., IL-1 type I receptor, TNF type I and II receptors, IL-2 receptor) are shed under different pathophysiological conditions. Webb12 apr. 2024 · Peripheral artery disease (PAD) commonly refers to obstructive atherosclerotic diseases of the lower extremities and affects approximately 8.5 million people in the United States and 200 million people worldwide (1, 2).Approximately 5 to 10% of patients with PAD progress to critical limb-threatening ischemia at 5 years (), with … ip location viewer